November, 2023 At the recent ACR Convergence 2023, the annual meeting of the American College of Rheumatology, important lupus clinical trial data and breakthrough foundational research were presented. Following are highlights of work funded by the Lupus Research Alliance or supported in partnership with industry through our clinical affiliate Lupus Therapeutics. CAR-T Cell Therapy is […] READ MORE
May 31, 2023 We are pleased to share encouraging news from EULAR, the annual meeting of the European Alliance of Associations for Rheumatology of Phase 2 data presented showing that upadacitinib improved SLE disease activity and time to first flare while lowering the need for steroids. Side effects were consistent with the known safety profile. Discovered and […] READ MORE
September 21, 2022 Lupkynis® (voclosporin) was just granted marketing authorization in the European Union as a new treatment for adults with lupus nephritis, the kidney damage associated with lupus. The drug had also been approved this past January in the U.S. to treat adults with lupus nephritis in combination with a background immunosuppressive medication in […] READ MORE
August, 2022 We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England Journal of Medicine showing that the investigational therapy litifilimab (BIIB059) lessened skin disease activity in cutaneous lupus erythematosus. There is a great unmet need for people with cutaneous lupus, a type of lupus with few treatment […] READ MORE
June 23, 2022 The Lupus Research Alliance (LRA) is pleased to award its 2022 Lupus Insight Prize (LIP) to Akiko Iwasaki, PhD, for her discovery of the link between endogenous retroviruses and systemic lupus erythematosus (SLE). The award was presented to Dr. Iwasaki at the 22nd Annual Meeting of the Federation of Clinical Immunology Societies […] READ MORE
NEW YORK, NY, June 9, 2022. The Lupus Research Alliance (LRA), the world’s leading private funder of lupus research, today announced inaugural recipients of Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research. The Diversity in Lupus Research Award funding mechanisms aim to address underrepresentation of minorities in the scientific research profession. Lupus […] READ MORE
June 2, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results presented at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress from a Phase 2 trial of its investigational biologic deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib […] READ MORE
June 1, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib is a potentially first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates […] READ MORE
March 24, 2022 Recognized for her contributions to lupus during 2022’s Women’s History Month, Dr. Jane Salmon chose to specialize in lupus research because it was there that she felt she could be of greatest value. “There were so many unknowns in lupus with all its complexity. Here was a disease primarily affecting young women […] READ MORE
Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] READ MORE
February 17, 2022 It’s with great pride that I share a sampling of the many extraordinary accomplishments of last year in our first Lupus Research Update of 2022. The Lupus Research Alliance (LRA) made important gains on many fronts—thanks to tremendous friends like you. I hope you share my pride because your support continues to be the catalyst behind every LRA accomplishment. […] READ MORE
February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY. A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […] READ MORE
